Cerebral small vessel disease (CSVD) represents a group of pathological processes affecting the small arteries, arterioles, capillaries, and venules of the brain. It is a major cause of vascular cognitive impairment and dementia, contributing to approximately 45% of all dementia cases worldwide. CSVD frequently co-exists with Alzheimer's disease (AD) and Parkinson's disease (PD) pathology, creating a complex interplay that accelerates cognitive decline. This mechanism page provides a comprehensive overview of CSVD types, pathophysiology, neuroimaging hallmarks, diagnostic criteria, and its relationship to major neurodegenerative diseases.
CSVD encompasses a heterogeneous group of vascular pathologies that share common features: damage to the small vessels of the brain, resulting in chronic ischemic changes, white matter pathology, and varied clinical manifestations ranging from cognitive impairment to stroke. The term "small vessel disease" refers to vessels with diameters less than 400 micrometers, including: [1]
The clinical significance of CSVD has grown substantially as neuroimaging techniques have improved, revealing that CSVD is far more prevalent than previously recognized and plays a critical role in the pathogenesis of multiple neurodegenerative conditions. [2]
Arteriolosclerosis is the most common form of CSVD and is strongly associated with age and hypertension. It involves: [3]
Hypertensive arteriolosclerosis primarily affects the penetrating arterioles of the basal ganglia, thalamus, and deep white matter. These vessels are "end-arteries" with limited collateral circulation, making them particularly vulnerable to ischemic damage. The resulting chronic hypoperfusion leads to white matter rarefaction, lacunar infarcts, and deep hemorrhages. [4]
Cerebral amyloid angiopathy involves the deposition of amyloid-beta (Aβ) in the media and adventitia of small to medium-sized cortical and leptomeningeal vessels. This is distinct from, but often coexists with, Alzheimer's disease neuropathology. Key features include: [5]
CAA is particularly important in the context of neurodegeneration because it represents a direct link between amyloid pathology in vessels and in brain parenchyma. The APP gene and its proteolytic processing play a central role in both CAA and AD. [6]
Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) is a hereditary small vessel disease caused by mutations in the NOTCH3 gene on chromosome 19. This condition exemplifies the genetic basis of CSVD and provides insights into underlying mechanisms: [7]
CADASIL demonstrates that genetic defects in small vessel function can produce the full spectrum of CSVD pathology, including white matter hyperintensities, lacunar infarcts, and cognitive decline. [8]
Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASL), also known as CARASIL, is caused by mutations in the HTRA1 gene. This condition shares features with CADASIL but has: [9]
The HTRA1 gene encodes a serine protease that regulates transforming growth factor-beta (TGF-β) signaling, suggesting important links between vascular biology and connective tissue homeostasis.
The neuroimaging manifestations of CSVD are characterized by the STRIVE (STandards for ReportIng Vascular changes on Neuroimaging) criteria, which provide standardized definitions for research and clinical practice.
White matter hyperintensities appear as hyperintense regions on T2-weighted and FLAIR MRI sequences. They represent:
WMH are classified by location:
The Fazekas scale provides a standardized rating system:
Lacunes are small (3-15 mm) cavities resulting from acute or chronic ischemic infarcts in the territory of deep penetrating arterioles. They appear as:
Cerebral microbleeds are small (2-10 mm) perivascular hemosiderin deposits visible as hypointense foci on susceptibility-weighted imaging (SWI) or gradient-echo T2*-weighted MRI:
Microbleeds indicate underlying vascular pathology and are associated with increased risk of intracerebral hemorrhage, particularly in patients on anticoagulation therapy.
Enlarged perivascular spaces (also called Virchow-Robin spaces) are fluid-filled spaces surrounding penetrating blood vessels. They appear as:
EPVS are thought to reflect impaired perivascular clearance, including dysfunction of the glymphatic system, and may be related to blood-brain barrier disruption.
CSVD contributes to brain atrophy through multiple mechanisms:
The endothelium is the primary target in CSVD, with dysfunction manifesting as:
Endothelial dysfunction in CSVD involves multiple signaling pathways, including diminished insulin signaling, impaired TGF-β signaling, and altered notch receptor function. These changes affect cerebral autoregulation—the ability to maintain constant cerebral blood flow despite changes in systemic blood pressure.
The blood-brain barrier (BBB) is a specialized interface between the blood and brain parenchyma, maintained by tight junctions between endothelial cells. In CSVD:
BBB breakdown allows peripheral proteins (e.g., fibrinogen, albumin) to enter the brain, triggering inflammatory responses and contributing to white matter damage. This process is closely linked to neuroinflammation and glial activation.
Cerebral hypoperfusion in CSVD results from:
Chronic hypoperfusion triggers:
The deep white matter is particularly susceptible to CSVD due to:
The relationship between CSVD and Alzheimer's disease is complex and bidirectional:
CSVD promotes AD pathology:
AD pathology contributes to CSVD:
This "vascular hypothesis" of AD suggests that addressing CSVD may be a therapeutic strategy for AD prevention and treatment.
Parkinson's disease shows significant overlap with CSVD:
The substantia nigra and basal ganglia are particularly vulnerable to hypoperfusion, which may contribute to motor symptoms in PD.
ALS demonstrates interesting connections to CSVD:
Frontotemporal dementia and related disorders show CSVD comorbidity:
Huntington's disease involves white matter degeneration that shares features with CSVD:
CSVD is a leading cause of vascular cognitive impairment (VCI), ranging from mild cognitive impairment to dementia:
The "dysexecutive syndrome" of VCI distinguishes it from the amnestic presentation of AD, though mixed pathology is common.
CSVD increases the risk of both:
NINDS-AIREN criteria for vascular dementia require:
Fazekas Scale for white matter lesions:
STRIVE criteria standardize MRI reporting:
Blood pressure control remains the cornerstone of CSVD treatment:
Other modifiable risk factors:
Given the role of neuroinflammation in CSVD:
For CAA:
Cerebral small vessel disease represents a critical nexus between vascular pathology and neurodegeneration. Its close relationship with Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions highlights the importance of vascular health in brain aging. The complex interplay between endothelial dysfunction, blood-brain barrier breakdown, chronic hypoperfusion, and neurodegenerative pathology creates a vicious cycle that accelerates cognitive decline. Understanding these mechanisms provides opportunities for therapeutic intervention, with vascular risk factor management remaining the most evidence-based approach. As neuroimaging and biomarker technologies advance, earlier detection and more precise characterization of CSVD will enable targeted treatments for this devastating condition.
Boespflug EL et al. Emerging MR imaging techniques for cerebral small vessel disease. Radiology. 2024. 2024. ↩︎
Litak J et al. 'Cerebral Small Vessel Disease and Parkinson''s Disease: A Review. Front Aging Neurosci. 2020'. 2020. ↩︎
Pasternak O et al. White matter abnormalities in premanifest Huntington's disease. J Neurol Sci. 2022. 2022. ↩︎
Huang Y et al. Cerebral amyloid angiopathy and its contribution to Alzheimer's disease. Mol Neurodegener. 2024. 2024. ↩︎
Cannistraro RJ et al. 'CNS small vessel disease: A clinical update. Neurology. 2019'. 2019. ↩︎
Fazekas F et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987. 1987. ↩︎
Blinder P et al. 'The cortical angiome: an interconnected vascular network. Nat Neurosci. 2013'. 2013. ↩︎
Hill J et al. Molecular insights into the blood-brain barrier in aging and Alzheimer's disease. Prog Neurobiol. 2024. 2024. ↩︎
Georgakis MK et al. Cerebral small vessel disease and incident Parkinson's disease. Neurology. 2023. 2023. ↩︎